About Our Development Program and Plans
What has EpiAxis discovered?
- The pivotal role that nuclear LSD1 plays in reprograming the epigenome in metastatic disease in relation to both tumour initiating and immune cells.
- The LSD1 mediated epigenetic signatures for chemotherapy and immunotherapy resistance in both tumour initiating cells and exhausted immune cells that drive recurrence of metastatic disease.
- Targeting the enriched nuclear pool of LSD1 reverses the resistant epigenetic signatures and removes immune checkpoint blockage, without the use of a checkpoint inhibitor, to prevent recurrence.
- A proprietary, non-catalytic, peptidomimetic way to superiorly inhibit the nuclear pool of LSD1 in both tumour initiating cells and in exhausted immune cells.
Why is EpiAxis best in class?
- We exclusively target the nuclear pool of LSD1 without catalytic interference.
- We provide three differentiated modes of action to target the innate nuclear pool of LSD1.
- We offer superior phenotype reversal and immune reinvigoration when compared to all known catalytic inhibitors.
- We offer superior removal of immune checkpoint blockage without the use of a checkpoint inhibitor when compared to all known catalytic inhibitors.
- We have proprietary LSD1 inhibitors with National Phase prosecutions active in eight jurisdictions.
What are our clinical findings to date?
- LSD1 inhibition reduces the mesenchymal burden of CTCs.
- LSD1 inhibition enhances effector memory T cells.
- LSD1 inhibition consistently increases IFNg and perforin expression in CD8+ T cells in remission.
- LSD1 inhibition offers superior immune reinvigoration regardless of HER2 status.
- LSD1 inhibition re-invigorates & re-programs T-cells & improves anti-tumour immune response.
- LSD1 inhibition re-programs CTLA4 protein expression in CD8+ T cells.
- LSD1 inhibition diminishes mesenchymal and stem-like phenotypes and in doing so, removes the CTC burden.
- EpiAxis’ EPI-110 candidates appear to be highly efficacious compared to phenelzine sulfate.
What are our development plans?
EpiAxis is now seeking a commercial partner to work with it to move its EPI-110 assets into a range of clinical studies in Europe and USA, which it expects will lead to regulatory approval in all major global markets.
EpiAxis believes that its EPI-110 candidates are not only ‘first in class’ but unequivocally ‘best in class’ inhibitors’ for solid tissue tumours. The Company further envisages that its EPI-110 candidates, as non-catalytic inhibitors, will be co-administered with chemotherapy and other IO agents, as Standard of Care, to prevent both mBC recurrence and other metastatic disease, in both the adjuvant and neoadjuvant setting.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder & Director at EpiAxis Therapeutics